Can genetic differences in GLP-1 and GIP receptors affect response to incretin therapy?

Incretin-based therapies like semaglutide and tirzepatide have significantly changed the management of type 2 diabetes and obesity.

• There is substantial variability in how individuals respond to these therapies.
• The variability in response is not fully explained by clinical factors alone.
• This suggests that other factors may influence the effectiveness of these treatments.

Simplified